Clinical Trials Logo

Spinal Muscular Atrophy Type 2 clinical trials

View clinical trials related to Spinal Muscular Atrophy Type 2.

Filter by:
  • None
  • Page 1

NCT ID: NCT05156320 Active, not recruiting - Clinical trials for Neuromuscular Diseases

Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam

SAPPHIRE
Start date: February 24, 2022
Phase: Phase 3
Study type: Interventional

This Phase 3 trial (Study SRK-015-003) is being conducted in patients ≥2 years old at Screening, who were previously diagnosed with later-onset spinal muscular atrophy (SMA) (i.e., Type 2 and Type 3 SMA) and are receiving an approved survival motor neuron (SMN) upregulator therapy (i.e., either nusinersen or risdiplam), to confirm the efficacy and safety of apitegromab as an adjunctive therapy to nusinersen and evaluate the efficacy and safety of apitegromab as an adjunctive therapy to risdiplam.

NCT ID: NCT03921528 Completed - Clinical trials for Neuromuscular Diseases

An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy

TOPAZ
Start date: April 22, 2019
Phase: Phase 2
Study type: Interventional

The TOPAZ study will assess the safety and efficacy of SRK-015 in later-onset Spinal Muscular Atrophy (SMA Type 2 and Type 3) in pediatric and adult patients.